SSY Group Secures Production Approval for Fenofibrate Choline Sustained-Release Capsules

Stock News07-16

SSY Group has announced that it has obtained a drug production registration certificate from China's National Medical Products Administration for Fenofibrate Choline Sustained-Release Capsules (135mg).

The product is classified as a chemical drug of category 4 and is considered to have passed the consistency evaluation.

Fenofibrate Choline Sustained-Release Capsules are primarily indicated for use in adults as an adjunct to diet to reduce triglyceride levels in patients with severe hypertriglyceridemia, and for the treatment of patients with primary hypercholesterolemia or mixed dyslipidemia.

Compared to traditional fenofibrate, Fenofibrate Choline acts directly, places a lower burden on the liver and kidneys, has no food intake restrictions for administration, and can be safely combined with statin medications. It represents a high-end, next-generation product for lowering triglycerides that addresses a critical clinical need.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177220905?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 12:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177220905","market":"nz","top_or_hot":-1,"title":"SSY Group Secures Production Approval for Fenofibrate Choline Sustained-Release Capsules","media":"Stock News","content":"<p>SSY Group has announced that it has obtained a drug production registration certificate from China's National Medical Products Administration for Fenofibrate Choline Sustained-Release Capsules (135mg).<br><br>The product is classified as a chemical drug of category 4 and is considered to have passed the consistency evaluation.<br><br>Fenofibrate Choline Sustained-Release Capsules are primarily indicated for use in adults as an adjunct to diet to reduce triglyceride levels in patients with severe hypertriglyceridemia, and for the treatment of patients with primary hypercholesterolemia or mixed dyslipidemia.<br><br>Compared to traditional fenofibrate, Fenofibrate Choline acts directly, places a lower burden on the liver and kidneys, has no food intake restrictions for administration, and can be safely combined with statin medications. It represents a high-end, next-generation product for lowering triglycerides that addresses a critical clinical need.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group Secures Production Approval for Fenofibrate Choline Sustained-Release Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group Secures Production Approval for Fenofibrate Choline Sustained-Release Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-16 12:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SSY Group has announced that it has obtained a drug production registration certificate from China's National Medical Products Administration for Fenofibrate Choline Sustained-Release Capsules (135mg).<br><br>The product is classified as a chemical drug of category 4 and is considered to have passed the consistency evaluation.<br><br>Fenofibrate Choline Sustained-Release Capsules are primarily indicated for use in adults as an adjunct to diet to reduce triglyceride levels in patients with severe hypertriglyceridemia, and for the treatment of patients with primary hypercholesterolemia or mixed dyslipidemia.<br><br>Compared to traditional fenofibrate, Fenofibrate Choline acts directly, places a lower burden on the liver and kidneys, has no food intake restrictions for administration, and can be safely combined with statin medications. It represents a high-end, next-generation product for lowering triglycerides that addresses a critical clinical need.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2460026573.USD","symbol_name":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1177220905","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177220905","pubTimestamp":1784175258,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SSY Group has announced that it has obtained a drug production registration certificate from China's National Medical Products Administration for Fenofibrate Choline Sustained-Release Capsules...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","02005":"石四药集团","BK1191":"制药"},"translate_title":"SSY集团获得非诺贝特胆碱缓释胶囊生产批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"SSY Group has announced that it has obtained a drug production registration certificate from China's National Medical Products Administration for Fenofibrate Choline Sustained-Release Capsules (135mg).The product is classified as a chemical drug of category 4 and is considered to have passed the consistency evaluation.Fenofibrate Choline Sustained-Release Capsules are primarily indicated for use in adults as an adjunct to diet to reduce triglyceride levels in patients with severe hypertriglyceridemia, and for the treatment of patients with primary hypercholesterolemia or mixed dyslipidemia.Compared to traditional fenofibrate, Fenofibrate Choline acts directly, places a lower burden on the liver and kidneys, has no food intake restrictions for administration, and can be safely combined with statin medications. It represents a high-end, next-generation product for lowering triglycerides that addresses a critical clinical need.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177220905","isCrawlerRequest":true}